Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
PK and Safety of Etelcalcetide in Chinese Hemodialysis Patients
NCT03283098Phase 1Completed
- Sponsor
- Amgen
- Start
- Mar 2018
- Primary completion
- Feb 2019
- Modality
- Peptides, Small Molecules
- Countries
- 1
01
Overview
Phase 1, randomised, double-blind trial in secondary hyperparathyroidism (SHPT) comparing Etelcalcetide with Placebo (2 arms). Primary endpoints: Time to Maximum Drug Concentration at Day 27, Maximum Observed Drug Concentration at Day 27 and 2 more. Started Mar 2018; status: completed.
02
Drugs
etelcalcetide
03
Conditions
secondary hyperparathyroidism (SHPT)
Beyond the preview
Go deeper on NCT03283098.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03283098.